The Cholangiocarcinoma Foundation (CCF) applauds the U.S. Food and Drug Administration (FDA) approval of AstraZeneca’s Imfinzi (durvalumab). “The Durvalumab approval is a big step forward and a significant change in trajectory for the treatment options available to this community. A new first-line treatment opens doors and increases opportunities for patients. We are grateful to all who participated in this clinical trial,” said Stacie Lindsey, CCF founder and CEO. “We’re proud to have worked ha